Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
13
CANF Quote, Financials, Valuation and Earnings
Last price:
$0.18
Seasonality move
:
-4.6%
Day range:
$0.17 - $0.20
52-week range:
$0.23 - $2.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.34x
P/B ratio:
0.61x
Volume:
1.5M
Avg. volume:
13.5M
1-year change:
-87.39%
Market cap:
$2.8M
Revenue:
$677.2K
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingCan-Fite BioPharma Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.25, Can-Fite BioPharma Ltd. has an estimated upside of 1251.35% from its current price of $0.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $0.18.
Fair Value
-
According to the consensus of 2 analysts, Can-Fite BioPharma Ltd. has 1251.35% upside to fair value with a price target of $3.25 per share.
CANF vs. S&P 500
-
Over the past 5 trading days, Can-Fite BioPharma Ltd. has underperformed the S&P 500 by -17.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Can-Fite BioPharma Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Can-Fite BioPharma Ltd. revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Can-Fite BioPharma Ltd. reported revenues of --.
Earnings Growth
-
Can-Fite BioPharma Ltd. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Can-Fite BioPharma Ltd. reported earnings per share of --.
Enterprise value:
-5.1M
EV / Invested capital:
--
Price / LTM sales:
1.34x
EV / EBIT:
--
EV / Revenue:
-6.85x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.61x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $853K | $810K | $743K | $197K | $155K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.8M | -$10.1M | -$8.2M | -$3.1M | -$1.8M | |
| EBITDA | -$12.8M | -$10.1M | -$8.2M | -$3.1M | -$1.8M | |
| Diluted EPS | -$8.04 | -$3.74 | -$1.86 | -$1.11 | -$0.36 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.4M | $20.1M | $9.2M | $9.9M | $9M | |
| Total Assets | $9.5M | $20.3M | $9.3M | $10M | $9.1M | |
| Current Liabilities | $1.3M | $2.7M | $2.5M | $2M | $2.1M | |
| Total Liabilities | $3.4M | $5.9M | $4.8M | $3.7M | $3.7M | |
| Total Equity | $6.1M | $14.4M | $4.5M | $6.2M | $5.4M | |
| Total Debt | -- | $71K | $14K | $13K | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.5M | -$4.3M | -$8.6M | -$1M | -$2.8M | |
| Cash From Investing | $21.5K | $20.1K | -$10.3K | $2.6K | -$530 | |
| Cash From Financing | $4.6M | $1.5M | $13.2M | $77.3K | $6M | |
| Free Cash Flow | -$5.5M | -$4.4M | -$8.6M | -$1M | -$2.8M | |
CANF
Sector
Market Cap
$2.8M
$28M
Price % of 52-Week High
7.54%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.54%
1-Year Price Total Return
-83.53%
-17.48%
Beta (5-Year)
0.982
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.25
200-day SMA
Sell
Level
$0.84
Bollinger Bands (100)
Sell
Level
0.36 - 0.66
Chaikin Money Flow
Sell
Level
-362.4M
20-day SMA
Sell
Level
$0.30
Relative Strength Index (RSI14)
Sell
Level
21.85
ADX Line
Sell
Level
21.99
Williams %R
Buy
Level
-93.8261
50-day SMA
Sell
Level
$0.38
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
327.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-24.8758)
Sell
CA Score
(Annual)
Level (-3.7817)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (6.8006)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
Stock Forecast FAQ
In the current month, CANF has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CANF average analyst price target in the past 3 months is $3.25.
-
Where Will Can-Fite BioPharma Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Can-Fite BioPharma Ltd. share price will rise to $3.25 per share over the next 12 months.
-
What Do Analysts Say About Can-Fite BioPharma Ltd.?
Analysts are divided on their view about Can-Fite BioPharma Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Can-Fite BioPharma Ltd. is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Can-Fite BioPharma Ltd.'s Price Target?
The price target for Can-Fite BioPharma Ltd. over the next 1-year time period is forecast to be $3.25 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CANF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Can-Fite BioPharma Ltd. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CANF?
You can purchase shares of Can-Fite BioPharma Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Can-Fite BioPharma Ltd. shares.
-
What Is The Can-Fite BioPharma Ltd. Share Price Today?
Can-Fite BioPharma Ltd. was last trading at $0.18 per share. This represents the most recent stock quote for Can-Fite BioPharma Ltd.. Yesterday, Can-Fite BioPharma Ltd. closed at $0.18 per share.
-
How To Buy Can-Fite BioPharma Ltd. Stock Online?
In order to purchase Can-Fite BioPharma Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CANF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CANF
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
0.61x
1.82x
Price / LTM sales
1.34x
1.60x
Growth Metrics
CANF
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.88%
Revenue (5-year growth)
-19.78%
6.5%
Earnings forecast
--
-$0.21
Profitability
CANF
Sector
Profitability FY 2024
$670.2K
$3.5M
Return on invested capital
--
-31.77%
Return on assets
--
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Aug
31
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
CANF
Sector
Total cash
$4.7M
$26.3M
Short term investments
$3.1M
$25.7M
Total assets
$9.1M
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
